Pipeline may offer options for combating diabetic eye disease

Intravitreally injected anti-VEGF drugs are undergoing investigation as researchers look for new treatment options.

Alcon finalizes deal to acquire Aerie Pharmaceuticals

According to the company, the deal adds pharmaceutical research and development capabilities and further expertise for future product pipeline. It also expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category.

Apellis reveals FDA acceptance of NDA amendment and new PDUFA date for pegcetacoplan for GA

The company noted the updated PDUFA goal date is February 26, 2023. The FDA also reiterated that they do not plan to hold an advisory committee meeting to discuss the application.